The timing may be right for a takeover of Cubist Pharmaceuticals Inc. (CBST)
The rising threat from drug-resistant germs and increasing calls from global health groups for more potent antibiotics is placing a premium on companies such as Cubist. The $4.8 billion drug developer is preparing to introduce four new medicines by 2020 to combat bacterial infections that have become resistant to older therapies because of decades of overuse.
Help employers find you! Check out all the jobs and post your resume
